Growblox Sciences Announces Patent Application for Treatments of Parkinson’s Disease, Alzheimer’s Disease, Huntington’s Disease and Dementia

Proprietary Complex Cannbinoid-Containing Mixtures for the Treatment of Neurodegenerative Disorders

Growblox Sciences, Inc. (OTCQB: GBLX) is pleased to announce the filing of the first of several patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC.  The current provisional patent application covers complex-cannabinoid-containing mixtures capable of enhancing dopamine secretion and protect neurons from the mitochondrial-induced free radical damage that occurs during disease progression in the brains of patients with Parkinson’s disease, Alzheimer’s disease, Lewy Body Dementia, and Huntington’s disease, among others. In an aging population, neurodegeneration associated with these disorders is a growing health burden according to the World Health Organization (2013).

For the past two years, GB Sciences has been working towards the creation of novel, patentable cannabis-based formulations under the leadership of Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc. “This patent application is the first in a series that were invented based on our novel approach to creating cannabis-based therapies. Unlike many other companies and researchers who try to reduce the natural complexity in the cannabis plant, we embrace it and it informs our therapeutic mixtures,” said Dr. Small-Howard. “Additionally, we test our mixtures in disease systems that include a natural diversity of human cannabis-receptors, not just CB1 and CB2 receptors, which are the only receptors studied by many leading cannabinoid researchers. Our fast and efficient screening system then evaluates the effectiveness of the cannabis-based mixtures containing dozens of individually acting agents in order to make effective therapies for different diseases. We intend to start with Parkinson’s disease because these patients are in great need of an effective therapeutic treatment. One additional benefit is that our Parkinson’s treatment does not contain substantial amounts of the psychoactive compound, delta-9 tetrahydrocannabinol.”

GB Sciences’ CEO, John Poss, said, “Our goal is to help the approximately one million patients in the US and ten million world-wide that are living with Parkinson’s disease through our life science research, and we anticipate being able to use the same research processes to create additional innovative therapeutic options for other underserved patient groups in the coming months. Through our current patent application, GB Sciences is poised to participate in the US biopharmaceutical market for neurological disorders, which is projected to reach $128.6 billion by 2020. While there are many regulatory hurdles in front of us, this opportunity dramatically expands the revenue potential for our company over the next five years.”


Source: PRNewswire

4 Condivisioni